Floatz logo

MDM2 INHIBITOR AMG-232

Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma

Telios Pharma, Inc.Small moleculePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
tl-895
Telios Pharma, Inc.
Phase 1/2CCC

Same molecule, other indications

MDM2 INHIBITOR AMG-232 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
B-cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →